搜索结果


   DDIT3

靶点ID:TCMBANKGE001205


靶点别名:AltDDIT3; C/EBPzeta; CEBPZ; CHOP; CHOP-10; CHOP10; GADD153


靶点描述:DNA damage inducible transcript 3


染色体:12


染色体位置:12q13.3


靶点类型:protein-coding


HERB_ID:-


HGNC_Link:2726


OMIM_Link:126337


Ensembl_Link:ENSG00000175197


   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族
TCMBANKHE003724 Rhizoma Curcumae longae 姜黄 To eliminate blood stasis, promote the flow of qi, stimulate menstrual discharge and relieve pain./Gallstones, jaundice, leukaemia in early stage and carcinoma of uterine cervix in early stage, chronic ulcer, chronic scab, blood stasis and qi stagnation, pain in chest and abdomen and rib-side, dysmenorrhea, amenorrhea, postpartum stasis stagnation abdominal pain, wind-heat impediment pain, knocks and falls, swollen welling abscess. tuberoid
TCMBANKHE003737/YEM-277 Nicotiana tabacum|Nicotiana tabacum L. 烟草 烟草 To move qi and relieve pain, resolve toxin and kill worms./Food stagnation, qi bind pain, welling abscess and flat abscess, clove sore, scab and lichen, snake bite, dog bite. 云南民族药物志:第二卷 leaf 阿昌族/傣族/德昂族/哈尼族/基诺族/景颇族/傈僳族/佤族/彝族

   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN000052 cannabidiol abn-cbd, (-)-4-(3-3,4-trans-p-menthadien-[1,8]-yl)olivetol; SCHEMBL16224872 C21H30O2 314.5 g/mol CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O
TCMBANKIN009187 bruceolide HMS2227D12; CHEMBL1564136; NCGC00247554-01; SMR000445627; MLS000728513 C21H26O10 438.43 CC1=C(C(=O)CC2(C1CC3C45C2C(C(C(C4C(C(=O)O3)O)(OC5)C(=O)OC)O)O)C)O
TCMBANKIN010402 aldosterone C21H28O5 360.4 g/mol CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4C(=O)CO)C=O)O
TCMBANKIN012066 arundine C17H14N2 246.31 g/mol C1=CC=C2C(=C1)C(=CN2)CC3=CNC4=CC=CC=C43
TCMBANKIN014768 aloe-emodim C1=CC2=C(C(=C1)O)C(=O)C3=C(C=C(C=C3C2=O)CO)O
TCMBANKIN017993 vitamin c D01CWN; Cell C; Ronotec 100; P 1110; Suncoat VC 40; D-threo-hex-2-enoic acid gamma-lactone; Citrovit; 2-o-(beta-d-glucopyranosyl)-ascorbic acid_qt; Juvamine; SCHEMBL13468284; Vasc; CHEBI:51384; D-Lyxoascorbic acid; CHEMBL1253320; AK481251; Chewcee; D-xyloascorbic acid; C8DQ5M1Y1E; MLS001066386; AK322241; Ascorbic acid, D-; AC1LD8K5; E 300; Scorbu C; 10504-35-5; Ascorbicacid; l(+)-ascorbic acid; ZINC100006137; L-ascorbate (vitamin C); (5S)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one; (+)-Ascorbic acid; UNII-C8DQ5M1Y1E; Ascorbinsaure; Ceklin; VC 97; (2S)-2-[(1R)-1,2-bis(oxidanyl)ethyl]-4,5-bis(oxidanyl)furan-3-one; Vicin; L-ascorbate acid; L-ascorbic acid; L-dehydroascorbic acid; ascorbate; D-threo-hex-2-enono-1,4-lactone; Kangbingfeng; D-Ascorbic acid; Viscorin 100M; ZINC100028197; (2S)-2-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroxy-3-furanone; L-Ascorbic acid (8CI,9CI); Proscorbin Redoxon Ribena Ronotec 100; Hex-2-enonic acid gamma-lactone, L-threo; (5S)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxy-2,5-dihydrofuran-2-one; Ascorbic acid; DL-Ascorbic acid; AKOS000278050; Cebion, gamma-lactone; F91F7DA3-A3D5-4FB4-A6E7-C497C48D192A; GTPL4651; SMR000471843; Xyloascorbic acid, L-; Rontex 100; Rovimix C; (2S)-2-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one; A828310 C6H8O6 176.12 C(C(C1C(=C(C(=O)O1)O)O)O)O
TCMBANKIN027464 Pine alcohol NaF or FNa [F-].[Na+]
TCMBANKIN036853 catalpol Catalpol; LMPR01020108; beta-D-Glucopyranoside, 1a,1b,2,5a,6,6a-hexahydro-6-hydroxy-1a-(hydroxymethyl)oxireno(4,5)cyclopenta(1,2-c)pyran-2-yl, (1aS-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha))-; 2415-24-9; Catalpinoside; NCGC00163523-01; beta-D-Glucopyranoside, 1a,1b,2,5a,6,6a-hexahydro-6-hydroxy- 1a-(hydroxymethyl)oxireno(4,5)cyclopenta(1,2-c)pyran-2-yl, (1aS-(1a-alpha,1b-beta,2-beta,5a-beta,6-beta,6a-alpha))-; Catalposide, des-p-hydroxybenzoyl-; De(p-hydroxybenzoyl)catalposide; (1AS-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha))-1a,1b,2,5a,6,6a-hexahydro-6-hydroxy-1a-(hydroxymethyl)oxireno(4,5)cyclopenta(1,2-c)pyran-2-yl-beta-D-glucopyranoside; C09773; EINECS 219-324-0 C15H22O10 362.33 C1=COC(C2C1C(C3C2(O3)CO)O)OC4C(C(C(C(O4)CO)O)O)O
TCMBANKIN036890 Parthenolide 20554-84-1; Prestwick_876 248.32 g/mol
TCMBANKIN036918 Thapsigargin 650.8 g/mol
TCMBANKIN050200 Zincpolyanemine 317.7 g/mol
TCMBANKIN057899 arsenicum;arsenic;as As 74.92159 g/mol [As]
TCMBANKIN057905 ferrum iron Fe 55.84 g/mol [Fe]
TCMBANKIN058025 styrene 105270-05-1; cinnamene; phenyl-ethylene; 61584-90-5; C19506; PPBRXRYQALVLMV-UHFFFAOYSA-N; 81415_FLUKA; 5487-EP2277945A1; MFCD00084450; CJ-04646; 52932-49-7; Benzene, ethenyl-, homopolymer; 20215_SUPELCO; Polystyrene, atactic; InChI=1/C8H8/c1-2-8-6-4-3-5-7-8/h2-7H,1H; S4972_SIAL; 81413_FLUKA; 51609-87-1; Styrene, analytical standard; AKOS000119972; Polystyrene standard, M.W. 1,300, Mw/Mn 1.06; 182435_ALDRICH; viny lbenzol; Chromosorb 102,100/120 50G; S0651; 9055-91-8; Polystyrene latex microsphere, 0.05 micron, 2.5 wt% dispersion in water; 189596_ALDRICH; 61584-89-2; 37291-EP2311803A1; Polysorb; 379514_ALDRICH; 00945_FLUKA; 79637-11-9; 5487-EP2269995A1; 5487-EP2295426A1; Cinnamene; 172641-48-4; 730985-59-8; NCGC00091056-01; 5487-EP2309584A1; CCRIS 564; 81406_FLUKA; AI3-24374; 81412_FLUKA; 117294-EP2287158A1; 78354-47-9; 1191987-17-3; 110866-50-7; W323306_ALDRICH; Benzene, ethenyl-, homopolymer, hydrogenated; Polystyrene standard, M.W. 2,200, Mw/Mn 1.06; UN 2055 (Salt/Mix); 149212-19-1; 100-42-5; Vinylbenzene, inhibited; Cinnamenol; 1263545-74-9; 5487-EP2305686A1; Styrene 5000 ng/microl in Methanol; Ethenylbenzene; 373601-20-8; Polystyrene latex microsphere, 1 micron, 2.5 wt% dispersion in water; Phenethylene; FT-0689054; Polystyrene standard, M.W. 13,000, Mw/Mn 1.06; Styrene, SAJ first grade, >=99.0%; Styrol [German]; Polystyrene latex microsphere, fluorescent, 6.0 micron, 2.5 wt% dispersion in water; 58033-91-3; Styren; CHEBI:27452; MALDI validation set polystyrene Mp 500-70'000 certified according to DIN; 5487-EP2295415A1; Styrene Resin (Med.M.Wt.); Polystyrene latex microsphere, 10.0 micron, 2.5 wt% dispersion in water; 327808_ALDRICH; Chromosorb 106, 60/80 MESH, 50GM; 171022-09-6; Styrene polymer; 461733_ALDRICH; 03565_FLUKA; Styren [Czech]; 851588-70-0; NCGC00091056-03; Polystyrene standard, M.W. 30,000, Mw/Mn 1.06; DTXSID2021284; 00928_FLUKA; 5487-EP2298313A1; Polystyrene high Mol. Wt.; 40494-15-3; 5487-EP2275418A1; Styropor (Salt/Mix); RP18837; 55465-00-4; 5487-EP2287168A2; 12770-88-6; 81418_FLUKA; Styrene, 99.5% stab. with 4-tert-Butylcatechol; 81402_FLUKA; 131495-39-1; 5487-EP2270113A1; 11120-46-0; KSC176E4F; 81834-12-0; Polystyrene (100-200 mesh, PEG crosslinked); PhCH=CH2; Styropol (Salt/Mix); 327794_ALDRICH; Styrene 100 microg/mL in Methanol; Vinylbenzol; Styropol SO; Phenylethene; Vinylbenzen [Dutch]; 459364_ALDRICH; NSC-62785; Benzene, ethenyl-; Styron; Cinnaminol; 5487-EP2289883A1; Styrene solution; CHEMBL285235; 1161074-30-1; Chromosorb 103; Stirolo [Italian]; Benzene-1,2,3,4,5-d5, 6-(ethenyl-1,2,2-d3)-; 53112-49-5; 5487-EP2289896A1; EINECS 273-493-5; Tox21_200808; Polystyrene latex microsphere, 2 micron, 2.5 wt% dispersion in water; 81407_FLUKA; 5487-EP2305685A1; Styrene monomer, inhibited; Vinyl benzene; 157929-02-7; Polystyrene latex microsphere, 20.0 micron, 2.5 wt% dispersion in water; 54596-41-7; 20202_SUPELCO; Ethylene, phenyl-; 5487-EP2280014A2; Styrene, 99%, stabilized 100ml; 5487-EP2380568A1; NCGC00091056-02; 00953_FLUKA; 1083095-63-9; W550159_ALDRICH; Polystyrene solution; Annamene; Chromosorb 101; 25038-60-2; 2-phenylethenyl; Polystyrene latex microsphere, 4.5 micron, 2.5 wt% dispersion in water; 00949_FLUKA; Polystyrene standard, M.W. 290,000, Mw/Mn 1.06; 68987-41-7; Ethylbenzene alkylate; 143365-EP2292620A2; Styreen; 86090-91-7; 327719_ALDRICH; 219782-52-2; 441772-62-9; 53986-84-8; 5487-EP2380867A1; 487021-46-5; 359762-95-1; Polystyrene latex microsphere, 6.0 micron, 2.5 wt% dispersion in water; KB-60631; 117294-EP2298762A2; 25086-18-4; 53395_FLUKA; 00946_FLUKA; 57657-06-4; 726192-11-6; Tox21_113245; 5487-EP2301924A1; NSC 62785; BIDD:ER0247; 39470-87-6; 143365-EP2287165A2; Polystyrene latex microsphere, 0.20 micron, 2.5 wt% dispersion in water; Polystyrene latex microsphere, 25.0 micron, 2.5 wt% dispersion in water; DSSTox_RID_76057; Phenylethylene, inhibited; 327824_ALDRICH; EC 202-851-5; 1198090-46-8; AC1Q2AAB; Polystyrene latex microsphere, 15.0 micron, 2.5 wt% dispersion in water; 5487-EP2311804A2; Polystyrene,flame retarding and impact resistant; 5487-EP2308832A1; 51876_FLUKA; 68441-35-0; Vinyl-benzene; 60880-98-0; DSSTox_CID_1284; 9044-64-8; Polystyrene standard, M.W. 5,200, Mw/Mn 1.06; STYRENE; NCGC00258362-01; Vinylbenzene; 23065-05-6; 644984-36-1; Polystyrene standard, M.W. 2,000,000, Mw/Mn 1.30; NCI-C02200; 143365-EP2287166A2; c0115; Bulstren K-525-19; 471865-10-8; Polystyrene standard, M.W. 25,000, Mw/Mn 1.06; Polystyrene latex microsphere, 1 micron, 10 wt% dispersion in water; Ethylenated benzene; 54578-24-4; 459410_ALDRICH; Polystyrene standard, M.W. 170,000, Mw/Mn 1.06; 81416_FLUKA; 00952_FLUKA; 00948_FLUKA; 8053AF; 00947_FLUKA; 327743_ALDRICH; Ethenylbenzene, 9CI; Polystyrene med Mol. Wt.; S0095; AN-24550; 5487-EP2311798A1; Styrene polymer-bound; 81401_FLUKA; 5487-EP2314577A1; 124229-31-8; CTK0H6242; Phenylethylene; Polystyrene latex microsphere, 1 micron, dry form; 459402_ALDRICH; Polystrene Standard broad 350'000; 20225_SUPELCO; Styron (Salt/Mix); Polystyrene standard, M.W. 4,000, Mw/Mn 1.06; 81409_FLUKA; 00926_FLUKA; 55128-06-8; Vinyl-polystyrene; Vinylbenzen [Czech]; 00951_FLUKA; 260975-79-9; 98444-30-5; Styrene monomer; Styrolene; 852837-17-3; ZB015538; Polystyrene latex microsphere, 0.50 micron, 2.5 wt% dispersion in water; 5487-EP2284165A1; 120037-99-2; FEMA Number 3234; Diarex hf 77; MCULE-4715354738; 5487-EP2311796A1; 182427_ALDRICH; 172867-64-0; 441147_ALDRICH; 161776-45-0; Styrene monomer, inhibited [UN2055] [Flammable liquid]; 45993_RIEDEL; 327786_ALDRICH; KS-00000VQV; 459372_ALDRICH; 327816_ALDRICH; Polystyrene latex microsphere, 75.0 micron, 2.5 wt% dispersion in water; Styreen [Dutch]; 81417_FLUKA; Polystyrene latex microsphere, 0.10 micron, 2.5 wt% dispersion in water; Styrene (monomer); Polystyrene standard, M.W. 123,000, Mw/Mn 1.08; 5487-EP2272849A1; Polystyrene standard, M.W. 900,000, Mw/Mn 1.10; 81403_FLUKA; TRA0031624; Polystyrene standard, M.W. 65,000, Mw/Mn 1.06; 5487-EP2298743A1; 155197-45-8; 63849-49-0; NCGC00091056-04; 81411_FLUKA; 81404_FLUKA; Polystyrene standard, MW ~ 1,300, MW/MN = 1.06 1g; 5487-EP2272832A1; Polystyrene standard, M.W. 3,350, Mw/Mn 1.10; 459461_ALDRICH; 360046-70-4; ZINC112958499; I01-4405; 9003-53-6; 47745U_SUPELCO; Benzene, ethylenated; Styrol (German); Diarex hf 77 (Salt/Mix); 5487-EP2295438A1; ethenyl-benzene; 117294-EP2275408A1; Polystyrene, minimum number average molecular weight (in amu), 50,000; 37291-EP2311802A1; Polystyrene standard, M.W. 400,000, Mw/Mn 1.06; 20217_SUPELCO; 5487-EP2308857A1; 40257U_SUPELCO; 12627-11-1; UNII-44LJ2U959V; ANW-14280; ZINC968269; 1160710-79-1; C07083; Styrene solution, certified reference material, 200 mug/mL in methanol; 1227265-55-5; 53397_FLUKA; 330353_ALDRICH; 171022-02-9; POLYSTYRENE; Styrol; 459399_ALDRICH; Styrole; Stirolo; Polystrene Standard 88'000; Polystrene Standard broad 206'000; HSDB 171; Chromosorb 106; 327778_ALDRICH; Styropor; RT-000109; 327751_ALDRICH; 5487-EP2292593A2; LS-304; 459380_ALDRICH; 5487-EP2270101A1; 5487-EP2311797A1; 81419_FLUKA; 44LJ2U959V; 5487-EP2314579A1; 5487-EP2298753A1; p-vinyl benzene; 327727_ALDRICH; CAS-100-42-5; A800199; 60328-46-3; AC1L1OWJ; FT-0659991; 5487-EP2311799A1; NSC62785; 81410_FLUKA; MolPort-001-779-766; EINECS 202-851-5; Polystyrene latex microsphere, 2 micron, 10 wt% dispersion in water; Polystyrene standard, M.W. 2,000, Mw/Mn 1.10; FEMA No. 3233; 459356_ALDRICH; BP-13451; 56451-72-0; 81414_FLUKA; Styrene, >=99%; 81408_FLUKA; Cinnamol; Polystyrene latex microsphere, 45.0 micron, 2.5 wt% dispersion in water; Styrene monomer, inhibited [UN2055] [Flammable liquid]; Styropol; 00954_FLUKA; Z966690906; Polystyrene standard, M.W. 50,000, Mw/Mn 1.06; Benzene-d5, ethenyl-d3-; STL283958; 137262-45-4; 331651_ALDRICH; 450383_ALDRICH; 120534-26-1; CARINE; Chromosorb 103,80/100,50G; 5487-EP2305668A1; Benzene, vinyl-; 144637-93-4; 5487-EP2308865A1; 56748-62-0; 5487-EP2295427A1; 124229-48-7; 330345_ALDRICH; MFCD00008612; WLN: 1U1R; NCGC00091056-05; 5487-EP2272935A1; 60120-16-3; 1187742-34-2; Styrene, ReagentPlus(R), 99.9%; UN2055; Polystyrene latex microsphere, 0.75 micron, 2.5 wt% dispersion in water; Chromosorb 102; Vinylbenzen; DSSTox_GSID_21284; F1908-0130; 157243-21-5; 430102_ALDRICH; Styrene; 5487-EP2295420A1; Polystyrene, hydrogenated; Styrene, ReagentPlus(R), contains 4-tert-butylcatechol as stabilizer, >=99%; Polystyrene latex microsphere, 90.0 micron, 2.5 wt% dispersion in water; Polystyrene standard, M.W. 650,000, Mw/Mn 1.06; Styrene-divinylbenzene Copolymer; SC-75569; 48347_SUPELCO C8H8 104.15 g/mol C=CC1=CC=CC=C1
TCMBANKIN058205 trans-resveratrol (E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene C14H12O3 228.24 g/mol C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O
TCMBANKIN058256 salidroside 10338-51-9; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[2-(4-hydroxyphenyl)ethoxy]oxane-3,4,5-triol; SCHEMBL17580247; (2R,3R,4S,5S,6R)-2-[2-(4-hydroxyphenyl)ethoxy]-6-methylol-tetrahydropyran-3,4,5-triol; ACon1_000366; 2-(4-Hydroxyphenyl)ethyl beta-D-glucopyranoside; Glucopyranoside, p-hydroxyphenethyl; Rhodosin; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[2-(4-hydroxyphenyl)ethoxy]tetrahydropyran-3,4,5-triol; MEGxp0_000478; Rhodioloside; beta-D-Glucopyranoside, 2-(4-hydroxyphenyl)ethyl; C14H20O7 300.3 g/mol C1=CC(=CC=C1CCOC2C(C(C(C(O2)CO)O)O)O)O
TCMBANKIN058272 esculetin AIDS-014709; CCG-38509; Cichoriin aglycon; KBioSS_001646; KUC108669N; NSC-26428; ZINC00057908; SM2XD6V944; HMS1570L22; ILEDWLMCKZNDJK-UHFFFAOYSA-N; NSC26428; Esculetol; ZX-AN021876; BPBio1_000968; MolPort-000-709-311; 6,7-Dihydroxycoumarin, 8CI; FCH1117729; ST24044991; 6,7-dihydroxy-2-chromenone; Coumarin, 6,7-dihydroxy-; NCGC00094873-01; KBio1_001374; NCGC00016425-01; Prestwick1_000940; AS-11863; LS-55161; CHEBI:490095; 2H-1-BENZOPYRAN-2-ONE,6,7-DIHYDROXY; RTR-013104; KSC-11-243-1; 7H-1-Benzopyran-7-one, 2,6-dihydroxy-; Esculetol); W-2566; DTXSID3075383; KS-0000017Z; 2,6-Dihydroxy-7H-chromen-7-one; NCGC00016425-04; Cichoriin aglucon; Spectrum5_000512; CD-051; ZX-AFC000486; BG01504928; KSC148K7L; SR-01000721907-2; HMS1921M14; ACM305356; E0386; Aesculetin (cichorigenin; NSC 26428; Aesculetin; s4711; EBD2197580; NCGC00016425-05; NCGC00094873-02; AK591206; AN-44203; BRN 0152788; 6,7-dihydroxy-2H-chromen-2-one; Esculatin; KBio2_006782; AB00489955; GTPL5180; SCHEMBL24641; 6,7-Dihydroxycoumarin; ACMC-20luwt; SR-01000721907; Esculin aglycon; SPECTRUM1500899; MFCD00006874; Cichorigenin; BIB6051; UNII-SM2XD6V944; I14-1622; BDBM34571; ST5306833; CHEMBL244743; TR-013104; MLS000069479; CAS-305-01-1; 6,7-Dihydroxy-2-chromenone; SMR000059055; C09263; 6,7-dihydroxychromen-2-one; esculetin ; HMS3373K09; DivK1c_006430; 3.05E+13; E-3401; HMS2233G24; InChI=1/C9H6O4/c10-6-3-5-1-2-9(12)13-8(5)4-7(6)11/h1-4,10-11; SpecPlus_000334; Spectrum4_001886; MCULE-4460039316; Esculetin; AC1NQYFH; Prestwick2_000940; A820407; Prestwick3_000940; Oprea1_719746; 6,7-bis(oxidanyl)chromen-2-one; Asculetine; ST079379; KBioGR_002416; AIDS014709; AC-18400; AKOS030559695; 91753-33-2; CJ-00486; KBio3_001584; FT-0620854; SMP2_000093; 305-01-1; AB0010898; 5-18-03-00202 (Beilstein Handbook Reference); CE0046; KBio2_001646; BSPBio_000880; Spectrum2_000586; 6,7-Dihydroxy-2H-1-benzopyran-2-one; SC-45867; DB-014626; CC-22332; BSPBio_002364; CTK3G3670; SDCCGMLS-0066669.P001; ALBB-023362; SPBio_000432; AC1Q7980; 6,7-Dihydroxy-2-benzopyrone; Prestwick0_000940; AJ-09788; C-06350; NCGC00016425-03; AK114506; 6,7-Dihydroxycoumarin, 98%; ZINC57908; EINECS 206-161-5; cid_5281416; BRD-K58149231-001-06-9; 2H-1-Benzopyran-2-one, 6,7-dihydroxy-; bmse000986; 4CN-0872; 6,7-dihydroxy-1-benzopyran-2-one; BN0888; HMS2097L22; Bio-0588; SPBio_003049; C9H6O4; E-3400; KBio2_004214; Spectrum_001166; Esculetin, analytical standard; 2H-1-Benzopyran-2-one, 6,7-dihydroxy- (9CI); N1764; 6,7-DIHYDROXYCOUMARIN; Coumarin, 6,7-dihydroxy- Esculetin; J10146; Esculetin, European Pharmacopoeia (EP) Reference Standard; 246573_ALDRICH; ZB002263; Esculin aglucon; 6,7-dihydroxy-coumarin; KB-50565; NCI60_002119; ANW-43483; 6,7-Dihydroxy-2H-chromen-2-one; D0YZ5G; NCGC00016425-06; Jsp005751; AX8020100; AKOS000276955; NCGC00016425-02; CCRIS 7065; 6,7-Dihydroxy-2H-chromen-2-one #; Spectrum3_000752; 6, 7-dihydroxycoumarin; aesculetin; 6,7-dihydroxycoumarin; 6,7-dihydroxy coumarin; CCG-38509; Cichoriin aglycon; KBioSS_001646; KUC108669N; NSC-26428; SM2XD6V944; HMS1570L22; ILEDWLMCKZNDJK-UHFFFAOYSA-N; NSC26428; Esculetol; ZX-AN021876; BPBio1_000968; MolPort-000-709-311; 6,7-Dihydroxycoumarin, 8CI; FCH1117729; ST24044991; Coumarin, 6,7-dihydroxy-; NCGC00094873-01; KBio1_001374; NCGC00016425-01; Prestwick1_000940; AS-11863; LS-55161; CHEBI:490095; 2H-1-BENZOPYRAN-2-ONE,6,7-DIHYDROXY; RTR-013104; KSC-11-243-1; 7H-1-Benzopyran-7-one, 2,6-dihydroxy-; Esculetol); W-2566; DTXSID3075383; KS-0000017Z; 2,6-Dihydroxy-7H-chromen-7-one; NCGC00016425-04; Cichoriin aglucon; Spectrum5_000512; CD-051; ZX-AFC000486; BG01504928; KSC148K7L; SR-01000721907-2; HMS1921M14; ACM305356; E0386; Aesculetin (cichorigenin; NSC 26428; Aesculetin; s4711; EBD2197580; NCGC00016425-05; NCGC00094873-02; AK591206; AN-44203; BRN 0152788; Esculatin; KBio2_006782; AB00489955; GTPL5180; SCHEMBL24641; ACMC-20luwt; SR-01000721907; Esculin aglycon; SPECTRUM1500899; MFCD00006874; Cichorigenin; BIB6051; UNII-SM2XD6V944; I14-1622; BDBM34571; CHEMBL244743; TR-013104; MLS000069479; CAS-305-01-1; 6,7-Dihydroxy-2-chromenone; SMR000059055; C09263; 6,7-dihydroxychromen-2-one; HMS3373K09; DivK1c_006430; 3.05E+13; E-3401; HMS2233G24; InChI=1/C9H6O4/c10-6-3-5-1-2-9(12)13-8(5)4-7(6)11/h1-4,10-11; SpecPlus_000334; Spectrum4_001886; MCULE-4460039316; Esculetin; AC1NQYFH; Prestwick2_000940; A820407; Prestwick3_000940; Oprea1_719746; 6,7-bis(oxidanyl)chromen-2-one; Asculetine; ST079379; KBioGR_002416; AC-18400; AKOS030559695; 91753-33-2; CJ-00486; KBio3_001584; FT-0620854; SMP2_000093; 305-01-1; AB0010898; 5-18-03-00202 (Beilstein Handbook Reference); CE0046; KBio2_001646; BSPBio_000880; Spectrum2_000586; 6,7-Dihydroxy-2H-1-benzopyran-2-one; SC-45867; DB-014626; CC-22332; BSPBio_002364; CTK3G3670; SDCCGMLS-0066669.P001; ALBB-023362; SPBio_000432; AC1Q7980; 6,7-Dihydroxy-2-benzopyrone; Prestwick0_000940; AJ-09788; C-06350; NCGC00016425-03; AK114506; 6,7-Dihydroxycoumarin, 98%; ZINC57908; EINECS 206-161-5; cid_5281416; BRD-K58149231-001-06-9; 2H-1-Benzopyran-2-one, 6,7-dihydroxy-; bmse000986; 4CN-0872; 6,7-dihydroxy-1-benzopyran-2-one; BN0888; HMS2097L22; Bio-0588; SPBio_003049; C9H6O4; E-3400; KBio2_004214; Spectrum_001166; Esculetin, analytical standard; 2H-1-Benzopyran-2-one, 6,7-dihydroxy- (9CI); N1764; 6,7-DIHYDROXYCOUMARIN; Coumarin, 6,7-dihydroxy- Esculetin; J10146; Esculetin, European Pharmacopoeia (EP) Reference Standard; ZB002263; Esculin aglucon; 6,7-dihydroxy-coumarin; KB-50565; NCI60_002119; ANW-43483; 6,7-Dihydroxy-2H-chromen-2-one; D0YZ5G; NCGC00016425-06; Jsp005751; AX8020100; AKOS000276955; NCGC00016425-02; CCRIS 7065; 6,7-Dihydroxy-2H-chromen-2-one #; Spectrum3_000752 C9H6O4 178.14 g/mol C1=CC(=O)OC2=CC(=C(C=C21)O)O
TCMBANKIN058310 cinnamaldehyde trans-Cinnamaldehyde, >=98%, FCC, FG; (E)-3-phenylacrolein; DSSTox_GSID_24834; 3-Phenyl-2-propenal; LS-378; UNII-SR60A3XG0F; (3E)-3-phenylprop-2-enal; Cinnamal; ZINC1532777; CS-0009609; (trans)-cinnamaldehyde; NSC-16935; NCGC00091512-02; NSC 16935; ST50213393; D0PJ3M; Aldehyd skoricovy; MolPort-004-288-292; Abion CA; BRN 1071571; 2-propenal, 3-phenyl-, (2E)-; trans-3-Phenylacrolein; FEMA No. 2286; transcinnamaldehyde; Cinnamaldehyde, trans-; Cinnamic aldehyde; DTXSID6024834; 3-Phenylpropenal; 3-Phenyl-2-propen-1-al; 3-phenylprop-2-enal; Cinnamaldehyde (trans), neat; AIDS-097032; BB_NC-2240; trans-Cinnamic aldehyde; NSC40346; TRANS-CINNAMALDEHYDE (SEE ALSO CINNAMALDEHYDE (104-55-2)); CCRIS 6222; trans-3-Phenyl-2-propenal; 3-Fenylpropenal [Czech]; CCRIS 3189; BBL010378; MLS002454394; SCHEMBL3441; NCGC00091512-05; ST5213393; AIDS097032; CNMA; CAS-14371-10-9; Zimtaldehyde; (2E)-3-phenylprop-2-enal; Cinnamaldehyde, United States Pharmacopeia (USP) Reference Standard; InChI=1/C9H8O/c10-8-4-7-9-5-2-1-3-6-9/h1-8H/b7-4; NCGC00259353-01; 2-Propenal, 3-phenyl-, (E)- (9CI); Cassia aldehyde; 3-Phenylacrylaldehyde; 3-Phenylacrolein; NCGC00257017-01; M181; SR60A3XG0F; W228605_ALDRICH; 14371-10-9; Hefty Dog and Cat Repellent; trans cinnamic aldehyde; (E)-Cinnamic aldehyde; NCI-C56111; NSC16935; BDBM50203065; 2-Propenal, 3-phenyl-; (2E)-3-phenylacrylaldehyde; AK-77787; A801001; trans-Cinnamaldehyde, >=99%; GTPL2423; CINNAMALDEHYDE (TRANS); AS-12078; Benzylideneacetaldehyde; Cinnamaldehyde [NF]; BRN 0605737; DB-003796; AC1LCUDE; 58840-EP2308879A1; trans-3-Phenylacrylaldehyde; 2-propenal,3-phenyl-,(E)-; NSC-40346; TR-001003; Tox21_111144; W228613_ALDRICH; 58840-EP2305682A1; STK397371; (2E)-3-Phenyl-2-propenal; KB-81236; NCGC00091512-06; C00903; cinnamaldehyde ; Cinnamaldehyde, (E)-; trans-Cinnamaldehyde, 99%; Tox21_201804; 2-Propenal, 3-phenyl-, (E)-; AK158901; AI3-00473; (E)-3-Phenyl-2-propenal; 104-55-2; MFCD00007000; 96320_FLUKA; R501736; ST24024694; (E)-3-phenyl-acrylaldehyde; 239968_ALDRICH; AJ-26812; Phenylacrolein; trans-Cinnamaldehyde; Aldehyd skoricovy [Czech]; ST2407775; W-205597; Cinnamylaldehyde; LS-850; EINECS 203-213-9; AC1Q6PPL; RL00215; ZINC01532777; ACN-035400; bmse010257; 4-07-00-00984 (Beilstein Handbook Reference); C9H8O; (E)-3-Phenyl-propenal; trans-Cinnamaldehyde, analytical standard; Cinnamic aldehyde (natural); NCGC00091512-07; trans-Cinnamylaldehyde; Tox21_303271; EC 203-213-9; C80687_ALDRICH; EPA Pesticide Chemical Code 040506; Cinnamyl aldehyde; RTR-001003; SMR000112334; AN-24684; beta-phenylacrolein; cinnamic aldehyde, (E)-isomer; CHEBI:16731; WLN: VH1U1R; I14-109742; (E)-3-phenylacrylaldehyde; RT-001454; I14-7336; 2-07-00-00273 (Beilstein Handbook Reference); Epitope ID:150921; trans-Cinnamaldehyde; trans-3-Phenylacrylaldehyde; NCGC00091512-01; DSSTox_RID_77548; AC1Q6BJW; trans cinnamaldehyde; CHEMBL293492; SBB028652; (E)-3-phenyl-2-propenal(E)-cinnamaldehyde; 3-Fenylpropenal; (E)-phenylvinyl aldehyde; trans-Cinmaldehyde; KJPRLNWUNMBNBZ-QPJJXVBHSA-N; Nat. Cinnamaldehyde; (E)-Cinnamaldehyde; NATURAL CINNAMIC ALDEHYDE; FEMA Number 2286; HMS2268O08; AKOS000119171; Cinnemaldehyde; beta-Phenylcrolein; SC-19143; HSDB 209; B99DD6C7-1C6D-4FE3-A172-54BFDB987683; 3-PHENYL-2-PROPENAL (TRANS); CINNAMALDEHYDE; Cinnamaldehyde, Vetec(TM) reagent grade, 93%; AI3-33275; NCGC00091512-04; e-cinnamaldehyde; Cinnamaldehyde, natural, >=95%, FG; (E)-3-phenylprop-2-enal; Acrolein, 3-phenyl-; AM20060482; BG01497386; 3-Phenyl-2-propenaldehyde; N1482; Cinnamaldehyde, 95% 100g; KB-76097; Caswell No. 221A; CINNAMALDEHYDE (SEE ALSO TRANS-CINNAMALDEHYDE (14371-10-9)); CJ-24256; DSSTox_CID_4834; MolPort-000-871-213; (E)-3-Phenylpropenal; Cinnamaldehyde, Natural; Trans- cinnamic aldehyde;(E)-Cinnamaldehyde;3-phenylpropenal;3-phenyl-2-propenalTrans- cinnamic aldehyde;(E)-Cinnamaldehyde;3-phenylpropenal;3-phenyl-2-propenal C9H8O 132.16 C1=CC=C(C=C1)C=CC=O
TCMBANKIN058416 chrysazin LTAN;danthron;9,10-Anthracenedione, 1,8-dihydroxy-; KBioGR_001944; ACon1_000135; Spectrum4_001682; NCI60_041443; 1,8-Dihydroxy-9,10-anthracenedione; 1,8-dihydroxyanthra-9,10-quinone; 1,8-Dihydroxyanthrachinon [Czech]; KBio2_002230; Roydan; Istan; InChI=1/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16; Chrysazin; Spectrum_001750; Modane; Usaf nd-59; Dantron; NSC 38626; AIDS-001375; EU-0099935; Danivac; EINECS 204-173-5; 1,8-Dihydroxy-9,10-anthraquinone; 117-10-2; Dionone; Laxanorm; CCRIS 3529; Dioxyanthrachinonum; KBio2_007366; Dorbanex; AI3-38117; NCGC00091367-02; NSC646568; Altan; NCGC00091367-01; Anthraquinone, 1,8-dihydroxy-; 1,8-Dihydroxyanthracene-9,10-dione; Laxanthreen; KBioSS_002230; MEGxp0_001693; NSC 646568; 1,8-Dihydroxyanthraquinone; C10312; component of Modane; Danthron [BAN]; D108103_ALDRICH; Laxipur; Duolax; CHEBI:3682; BSPBio_002259; ZINC03860369; ST5330603; AIDS001375; Dantrona [INN-Spanish]; Dorbane; KBio3_001479; Zwitsalax; NSC7210; SPECTRUM211468; Scatron D; SMR000059018; Spectrum5_000324; Chrysazine; NSC38626; Danthron; Spectrum3_000650; Pastomin; Dantrone [INN-French]; KBio1_000284; MLS000069608; 1,8-Dihydroxyanthrachinon; component of Doxidan; IDI1_000284; Laxipurin; Antrapurol; DivK1c_000284; Diaquone; Bancon; Neokutin S; Dantronum [INN-Latin]; NCIMech_000114; Spectrum2_000603; 343235-40-5; Istizin; 32073-07-7; component of Doxan; SPBio_000506; KBio2_004798; component of Dorbantyl; 1,8-Dihydroanthraquinone; NINDS_000284; WLN: L C666 BV IVJ DQ NQ; 1,4,5,8-Tetroxyantraquinone; Prugol;danthron; Chrysazine; Danthron; CAS-117-10-2; Z4XE6IBF3V; NCGC00091367-05; 9,10-Anthracenedione, 1,8-dihydroxy-; KBioGR_001944; ACon1_000135; 3nsq; Spectrum4_001682; NCI60_041443; 1,8-Dihydroxy-9,10-anthracenedione; 1,8-bis(oxidanyl)anthracene-9,10-dione; Danthron [USP]; 1,8-Dihydroxyanthrachinon [Czech]; KBio2_002230; Roydan; DSSTox_CID_328; Istan; BBL013161; InChI=1/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16; dihydroxyanthraquino ne; 1,8-Dihydroxyanthraquinone, Vetec(TM) reagent grade, 96%; Chrysazin; Spectrum_001750; Modane; Usaf nd-59; HMS2091A09; Dantron; NSC 38626; 9, 1,8-dihydroxy-; Dantron, INN; NSC755828; SBI-0051330.P003; EU-0099935; Dantron [INN]; CCG-35470; DB04816; Danivac; HMS3715F08; D0J0EL; ST50330603; NCGC00091367-06; UNII-Z4XE6IBF3V; EINECS 204-173-5; Dantron (Chrysazin; 8,9-DIHYDROXYANTHRACENE-1,10-DIONE; 1,8-Dihydroxy-9,10-anthraquinone; danthro-lax; HSDB 7764; Dionone; 117-10-2; Laxanorm; CCRIS 3529; NSC-646568; Criasazin; Dioxyanthrachinonum; KBio2_007366; RTR-003068; Dorbanex; ANW-17004; SBB057973; AI3-38117; NCGC00258539-01; dianthon; Danthron (1,8-Dihydroxyanthracene-9,10-dione); STK238373; HMS500O06; 8,9-dihydroxy-1,10-anthraquinone; NSC646568; ZX-AT013456; NCGC00091367-02; Altan; 1,8-dioxyanthraquinone; NCGC00091367-01; Anthraquinone, 1,8-dihydroxy-; Laxanthreen; 1,8-Dihydroxyanthracene-9,10-dione; SR-01000721864-2; AB1006759; I14-16739; KBioSS_002230; 1,8-Dihydroxyanthra-9,10-quinone #; MEGxp0_001693; KS-00000W95; NSC 646568; 1,8-Dihydroxyanthraquinone; MolPort-000-564-798; C10312; AC1L1EU5; component of Modane; Danthron [BAN]; Laxipur; Duolax; DTXSID9020328; Laxapur; LTAN; 1,8-Dihydroxy-9,10-anthracenedione, 9CI; MFCD00001211; DSSTox_GSID_20328; CHEBI:3682; ZINC3860369; Danthron, BAN; BRD-K10065684-001-03-3; BSPBio_002259; danthrone; OR61434; NCGC00091367-04; CS-4392; LS-587; BG01537787; ZX-AS004388; SR-01000721864; s4561; NSC-7210; Dantrona [INN-Spanish]; FT-0624445; Dorbane; 1,8-Dihydroxyanthraquinone, 96%; KBio3_001479; Zwitsalax; CHEMBL53418; CTK3J0719; Tox21_111122; ARONIS23892; KSC490O1T; NSC7210; SPECTRUM211468; Scatron D; ACMC-20mzuc; SMR000059018; 140861-59-2; Spectrum5_000324; Dantrona; BG00609013; D07107; BDBM11316; AB00051961_09; Chrysazine; NSC38626; Spectrum3_000650; Pastomin; Dantrone [INN-French]; Dorbanex (Salt/Mix); KBio1_000284; MLS000069608; BRD-K10065684-001-02-5; CHRYSAZIN, PRACT; Dantronum; NSC-755828; 1,8-Dihydroxyanthrachinon; 1,8-dihydroxy-9,10-dihydroanthracene-9,10-dione; Tox21_200986; Anthraquinone-related compound; Pilules Vinchy N.F. (TN); component of Doxidan; IDI1_000284; D0563; DSSTox_RID_75516; QBPFLULOKWLNNW-UHFFFAOYSA-N; Anthraquinone,8-dihydroxy-; Laxipurin; MCULE-5800615690; 1,8-Dihydroxyanthracene-9,10-dione (Danthron); A803710; Antrapurol; DivK1c_000284; HS-1003; Diaquone; Bancon; CTK0F1106; HY-B0923; AN-43229; 1,8-dihydroxy-anthraquinone; Dorbantyl; 1,8-Dihydroxyanthra-9,10-quinone; Dorbantyl (Salt/Mix); Neokutin S; Dantronum [INN-Latin]; AK208660; NCIMech_000114; TR-003068; Pharmakon1600-00211468; Spectrum2_000603; 343235-40-5; NCGC00091367-07; SCHEMBL83688; Istizin; SPBio_000506; component of Doxan; NSC-38626; 1,8 Dihydroxy Anthraquinone; 32073-07-7; Dantron (INN); W-108572; KBio2_004798; NCGC00091367-03; component of Dorbantyl; 1,8-Dihydroanthraquinone; R229; Dantrone; NINDS_000284; AKOS001583216; WLN: L C666 BV IVJ DQ NQ; 1,4,5,8-Tetroxyantraquinone; BB_NC-0487; C14H8O4; Tox21_111122_1; RP28420; Prugol; Istizine; BBC/171; 1,10-Anthracenedione, 8,9-dihydroxy- C14H8O4 240.21 g/mol C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O
TCMBANKIN058519 (-)-epigallocatechin-3-gallate; (-)-epigallocatechin 3-o-gallate;epigallocatechin gallate; galloyl-l-epigallocatechol; epigallocatechin 3-gallate; (-)-epigallocatechin gallate; KBio2_000796; SpecPlus_000277; 50299_FLUKA; Spectrum3_000244; KBioGR_002002; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] ester; MLS000758300; DivK1c_006373; (−)-Epigallocatechin gallate; EGCG; SPBio_000035; (−)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; KBioSS_000796; Epigallocatechin gallate; Spectrum4_001541; (-)-epigallocatechin 3-gallate; Tea catechin; AIDS000674; KBio2_005932; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3-chromanyl] ester; KBio1_001317; 989-51-5; AIDS-000674; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); KBio2_003364; Galloyl-L-epigallocatechol; SDCCGMLS-0066550.P001; (-)-Epigallocatechol gallate; ACon1_001054; Spectrum5_000102; Green tea extract; MEGxp0_001166; C09731; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; (-)-Epigallocatechin gallate; CCRIS 3729; Teavigo; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Spectrum2_000168; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; (−)-cis-3,3′,4′,5,5′,7-Hexahydroxy-flavane-3-gallate; CHEBI:4806; (-)-epigallocatechin-3-gallate ; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; SPECTRUM210239; E4143_SIAL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; Spectrum_000316; (-)-EGCG; KBio3_001128; BSPBio_001628; Epigallocatechol, 3-gallate, (-)-; Epigallocatechin-3-gallate; E4268_SIAL; epigallocatechin gallate ; epigallocatechin-3-gallate; (-)epigallocatechin-3-gallate ; EGCG; 989E515; [5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 2,3,4-trihydroxybenzoate; HMS2051K21; CS-1258; AC1L22IG; AK165605; Green tea polyphenols, Anagen; (-)-Epigallocatechin-3-O-gallate, United States Pharmacopeia (USP) Reference Standard; AKOS015918182; CAS-989-51-5; Epigallocatechin gallate, primary pharmaceutical reference standard; W-5069; (-)-cis-3,3',4',5,5',7-Hexahydroxy-flavane-3-gallate; (-)-Epigallocatechin gallate, analytical standard; Q-100914; DSSTox_RID_78830; AN-15867; DSSTox_GSID_29889; (-)-Epigallocatechol gallate; FT-0604392; NCGC00164319-04; Green tea extract; MEGxp0_001166; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; N1874; CHEBI:4806; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; BG00814299; HMS3649E08; D0E9DB; Epigallocatechol, 3-gallate, (-)-; (-)-EpigallocatechinGallateHydrate; Epigallocatechin-3-gallate; AB0014381; BQM438CTEL; NC00078; ST51055716; Epigallocatechin gallate, Pharmaceutical Secondary Standard; Certified Reference Material; SpecPlus_000277; Spectrum3_000244; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl-3,4,5-trihydroxybenzoate; MLS000758300; (-)-Epigallocatechin gallate (EGCG); CCG-38378; Gallic acid, 3-ester with epigallocatechol, (-)-; SR-01000946601-1; NCGC00164319-01; (-)-cis-3,4-Dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1(2H)-benzopyran-3-yl Gallate; NCGC00164319-06; DSSTox_CID_567; MCULE-3341525983; Epigallocatechin monogallate, B; Tox21_303457; SAM001247031; 4awm; K791; 989-51-5; SR-01000946601; MFCD00075940; EGCG analogs; Galloyl-L-epigallocatechol; NCGC00164319-03; (-)-Epigallocatechin gallate, >=80% (HPLC), from green tea; Spectrum5_000102; CPD000449288; (-)-Epigallocatechin gallate; LMPK12030005; E0694; Teavigo; Epigallocatechin gallate analogs, Anagen; Epigallocatechin-3-monogallate; ACN-035233; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; Sunphenon; Epigallocatechin gallate(EGCG); s2250; PF-EGCg 90; 3,4-Dihydro-5,7-dihydroxy-2R-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3R-yl-3,4,5-trihydroxybenzoate; 3,4,5-Trihydroxybenzoic acid (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; MLS001424000; (-)-EGCG; ZINC3870412; KBio2_000796; EGCG cpd; KBioGR_002002; Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2R-cis)-; EGCG, Anagen; NCGC00257243-01; Tox21_201468; L-Epigallocatechin gallate; cid_65064; SPBio_000035; BG01747388; Epigallocatechin gallate; KBioSS_000796; Spectrum4_001541; (-)-epigallocatechin 3-gallate; DB12116; EPIGALOCATECHIN GALLATE; ANTIOXIDANT MODEL (TRAMP) -EPIGALLOCATECHIN GALLATE; KBio2_005932; I14-7747; D0U2BH; MCULE-7760530136; 2kdh; Epigallocatechin gallate, Anagen; AOB2839; SDCCGMLS-0066550.P001; 863-65-0; FR-109; ST097428; ACon1_001054; LS-2197; CCRIS 3729; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Epigallocate; GTPL7002; BDBM50070942; C22H18O11; GTPs,Anagen; SCHEMBL35258; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; MolPort-001-741-358; DivK1c_006373; KB-206444; SR-01000759328; Teavigo;; EGCG; (-)-EPIGALLOCATECHIN GALLATE (GREEN TEA EXTRACT); HY-13653; (-)-Epigallocatechin gallate, >=95%; NCGC00259019-01; Tea catechin; DS-9030; SR-01000759328-6; SR-01000759328-5; KDH; AC1Q5X0Z; KBio1_001317; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxyb enzoate; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); NVP-XAA 723; KBio2_003364; EBD2138593; FT-0082796; NCGC00164319-02; C09731; (-)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; UNII-BQM438CTEL; DTXSID1029889; WMBWREPUVVBILR-WIYYLYMNSA-N; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; (-)-Epigallocatehin gallate; Spectrum2_000168; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; (-)-Epigallocatechin gallat; SPECTRUM210239; Epigallocic acid; Epigallocatcchin Gallate; KS-0000132O; BP-30205; CHEMBL297453; SC-47284; Spectrum_000316; 3oob; (-)-Epigallocatechin gallate, >=97.0% (HPLC); KBio3_001128; BSPBio_001628; epigallo-catechin gallate C22H18O11 458.4g/mol C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
TCMBANKIN058826 2',4,4'-trihydroxy-3'-geranylchalcone xanthoangelol C25H28O4 392.5 g/mol CC(=CCCC(=CCC1=C(C=CC(=C1O)C(=O)C=CC2=CC=C(C=C2)O)O)C)C
TCMBANKIN059159 capsaicin 8-Methyl-N-vanillyl-6-nonenamide, (E)-; AKOS007930159; Bio-0615; GTPL2486; Bio2_000748; EPA Pesticide Chemical Code 070701; Zostrix HP; S07O44R1ZM; TC-030399; 360376_ALDRICH; NCGC00017337-07; Citrus Aurantium 30%; AK589917; ZOSTRIX (TN); HMS2230O23; D0U5CE; HMS1989N10; IDI1_034018; DSSTox_GSID_20241; Isodecenoic acid vanillylamide; NGX-7325; NCGC00017337-04; HMS1791N10; NCGC00090853-08; NCGC00090853-11; KBio3_000536; (E)-8-Methyl-N-vanillyl-6-nonenamide(8cl); NSC-757844; M2028_SIGMA; E-CAPSAICIN; Capsaicin, from Capsicum sp., >=50% (HPLC); (6E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; MCULE-8056866140; Capsaicin [USP:INN]; NCGC00257869-01; 6-Nonenamide, 8-methyl-N-vanillyl-, (E)-; DB06774; trans-N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; SMR000718774; KBioGR_000268; MEGxp0_001448; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (E)-; Caswell No. 158; Prestwick2_000879; KBio1_000354; FEMA No. 3404; Capsaicin, analytical standard; N735; HMS3649N15; SBI-0052593.P002; AJ-26667; BRD-K50590187-001-06-6; CAS_404-86-4; NCGC00017337-02; HMS1921H11; 8-Methyl-N-vanillyl-trans-6-nonenamide; 21750_FLUKA; ZINC01530575; Vanilloid; YKPUWZUDDOIDPM-SOFGYWHQSA-N; MR3H3; (E)-N-((4-Hydroxy-3-methoxyphenyl)-methyl)-8-methyl-6-nonenamide; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (6E)-; HMS1570P19; capsaicin ; Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8 -methyl-, (E)-; KBio3_000535; Zostrix (TN); KBio2_000783; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6E)-; NCGC00017337-06; Capsaicin, European Pharmacopoeia (EP) Reference Standard; Capsicin; N-(3-Methoxy-4-hydroxybenzyl)-8-methyl-6-nonenamide; KBioSS_000783; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide, (E)-; Bitter orange extract 30%; N-(4-Hydroxy-3-methoxybenzyl)-8-methylnon-trans-6-enamide; SR-05000001861-5; Capsaicin, certified reference material, TraceCERT(R); CAPSAICIN, NATURAL; DSSTox_RID_75455; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (E)-; Capsaicin, Pharmaceutical Secondary Standard; Certified Reference Material; N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; depletes Substance P; trans-8-Methyl-N-vanillyl-6-nonenamide; BDBM20461; MolPort-001-742-263; 1217899-52-9; NCGC00090853-03; SR-05000001861; Spectrum_000303; UPCMLD-DP092:001; Capsaicin, >=95%, from Capsicum sp.; Capsaicin (transdermal patch formulation, neuropathic pain); I01-2469; Nonenamide, 8-methyl-N-vanillyl-, (E)-; SR-05000001861-9; CC0144; Transacin; AC1Q46B3; SDCCGMLS-0066678.P001; SR-05000001861-6; Axsain; AN-23437; (6E)-N-{[4-hydroxy-3-(methyloxy)phenyl]methyl}-8-methylnon-6-enamide; (E)-N-(4-Hydroxy-3-methoxybenzyl); (E)8-methyl-N-vanillyl-6-Nonenamide; CCRIS 1588; Capsaicin (JAN/USP); Capsaicin (Natural); trans-Capsaicin-d3; N0C781; trans-8-Methyl-N-vanillylnon; M1149; SC-19636; (E)-N-(4-hydroxy-3-methoxy-benzyl)-8-methyl-non-6-enamide; Styptysat; HMS2097P19; NCGC00017337-11; KBio3_002417; neurotoxic; CHEMBL294199; Capsaicin (in oleoresin of capsicum); NCGC00090853-01; N-(4-hydroxy-3-methoxy-benzyl)-8-methyl-non-6-enamide; Capsaicin [USAN]; Capsicine; NCGC00017337-08; NCGC00017337-09; C06866; N-[(4-hydroxy-3-methoxy-phenyl)methyl]nonanamide; NGX-1998; Tox21_110817; SCHEMBL8086; UNII-S07O44R1ZM; NSC 56353; (E)-N-[(4-HYDROXY-3-METHOXYPHENYL)METHYL]-8-METHYL-6-NONENAMIDE; BDBM86537; LMFA08020085; N-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-non-6-enamide; KBio2_002836; trans-8-methyl-N-vanillyl-6-nonenamide; NCGC00090853-06; CHEBI:94524; NCGC00090853-09; NCGC00090853-02; Bio2_000268; HMS3402N10; Prestwick_204; Prestwick3_000879; 8-Methyl-N-vanillyl-6E-nonenamide; Spectrum4_001739; 8-Methyl-N-Vanillyl-6-Nonenamide; N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide; BSPBio_001548; LS-2138; Capsaicin, United States Pharmacopeia (USP) Reference Standard; KBioGR_002158; EINECS 206-969-8; Bio1_000468; SPBio_002878; KBio2_000268; MFCD00017259; Bio1_001446; nchembio862-comp2; 6-Nonenamide, (E)-N-((4-hydroxy-3-methoxy-phenyl)methyl)-8-methyl; NSC-56353; NSC757844; DTXSID9020241; Ausanil; HMS501B16; HMS2092D21; EI-125; NCGC00090853-04; AK113598; NCI-C56564; Qutenza; SR-05000001861-4; [(E)-N-(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide; (6E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; Adlea; MLS002154049; (E)-8-Methyl-N-vanillyl-6-nonenamide; Pharmakon1600-01501128; Spectrum5_000538; (e)-n-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; 6-Nonenamide, (E)-; SCHEMBL8085; AB00053098-11; Capsaicin [in oleoresin of capsicum]; CJ-23980; NCGC00017337-12; HSDB 954; NGX 4010; CAS-404-86-4; BRN 2816484; 4CH-016296; NSC56353; IDI1_000354; RTC-030399; (E)-Capsaicin; TL8002946; NCGC00017337-05; CS-1518; Mioton; BG01597556; DivK1c_000354; 12084_FLUKA; Bio1_000957; AC-10114; AC1LU7K3; UPCMLD-DP092; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; TQ-1018; FT-0082538; Zostrix; NCGC00017337-03; AB00053098_12; SPECTRUM1501128; KS-5181; Prestwick1_000879; Capsaicin, from natural source; NCGC00017337-13; n-(4-hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide; Spectrum2_000770; NSC_2548; Prestwick0_000879; BPBio1_001053; NCGC00090853-10; C18H27NO3; NCGC00090853-12; W-5044; CAPSAICINE; SR-05000001861-1; Tox21_200315; HMS1361N10; D00250; (6E)-N-(4-Hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide #; Spectrum3_001449; HY-10448; (E)-N-[(4-Hydroxy-3-methoxyphenyl)-methyl]-8-methyl-6-nonenamide; BSPBio_002917; ST057183; KBio2_005919; ZINC1530575; SPBio_000820; N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; NCGC00017337-10; CCG-39908; STL372889; N-[(4-hydroxy-3-methoxyphenyl)methyl]-6E-8-methyl-nonenamide; Capsaicin Patch; UPCMLD-DP092:002; NGX-3781; BBL027836; (E)-N-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-non-6-enamide; Capsaicin (8-Methyl-N-vanillyl-6-nonenamide); 912457-62-6; HMS2089N11; Capsaicin; epsilon-capsaicin; (E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; NGX-4010; 6-Nonenamide, 8-methyl-N-vanillyl-, (E)- (8CI); KBioSS_000268; 21748_FLUKA; Citrus Aurantium Extract; KBio2_005404; TNP00277; trans-Capsaicin; CHEBI:3374; Capsaicin(Qutenza); CITRUS AURANTIUM PE; CAPSAICIN (2444-46-4 NONIVAMIDE (SYNTHETIC CAPSAICIN)); N1667; BSPBio_000957; 4-13-00-02588 (Beilstein Handbook Reference); BRD-K37056290-001-01-1; KBio2_003351; NCGC00090853-07; SMP2_000337; NINDS_000354; Isodecenoate; DSSTox_CID_241; ALGRX 4975; 404-86-4; CAPSAICINOIDS;Vanilloid;campsiol;capsaicin C18H27NO3 305.41 CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC
TCMBANKIN059258 dihydrocapsacine Dihydrocapsaicin; CHEBI:46932; Nonanamide, 8-methyl-N-vanillyl-; ZINC02522581; A813700; M1022_SIGMA; N-[(4-Hydroxy-3-methoxy-phenyl)methyl]-8-methyl-nonanamide; N-(4-hydroxy-3-methoxybenzyl)-8-methylnonanamide; N-[(3-methoxy-4-oxidanyl-cyclohexa-2,4-dien-1-yl)methyl]-8-methyl-non-6-enamide; NCGC00094119-02; TNP00314; ST057532; dihydrocapsaicin; 19408-84-5; 6,7-Dihydrocapsaicin; EU-0100782; NCGC00015645-01; N-(4-hydroxy-3-methoxy-benzyl)-8-methyl-pelargonamide; N-[(4-hydroxy-3-methoxy-1-cyclohexa-2,4-dienyl)methyl]-8-methyl-6-nonenamide; 8-Methyl-N-vanillylnonanamide; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methylnonanamide; BRN 2815150; Dihydrocapsacine; Nonanamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl- (9CI); Lopac0_000782; N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnonanamide; NCGC00015645-02; Lopac-M-1022; CCRIS 1589 C18H29NO3 307.4 g/mol CC(C)CCCCCCC(=O)NCC1=CC(=C(C=C1)O)OC
TCMBANKIN059336 tauroursodeoxycholic acid tauroursodeoxycholicacid; ursodeoxycholicacid; ursodeoxycholic acid C26H45NO6S 499.7 g/mol CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C
TCMBANKIN059435 2- Butenal C4H6O 70.09 g/mol CC=CC=O
TCMBANKIN059452 ethyl aldehyde C2H4O 44.05 g/mol CC=O
TCMBANKIN060029 parthenolide C15H20O3 248.32 g/mol CC1=CCCC2(C(O2)C3C(CC1)C(=C)C(=O)O3)C
TCMBANKIN060532 corosolic acid C30H48O4 472.7 g/mol CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CC(C(C5(C)C)O)O)C)C)C2C1C)C)C(=O)O
TCMBANKIN060545 Uosolic Acid C30H48O3 456.7 g/mol CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1C)C)C(=O)O
TCMBANKIN060862 shogaol C17H24O3 276.4 g/mol CCCCCC=CC(=O)CCC1=CC(=C(C=C1)O)OC
TCMBANKIN060889 delta(9)-tetrahydrocannabinol C21H30O2 314.5 g/mol CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O
TCMBANKIN060892 tetrahydrocannabinol delta8 CCCCCC1=CC2=C(C3C=C(CCC3C(O2)(C)C)C)C(=C1)O
TCMBANKIN060958 oleic acid;cis-oleic acid;oleinic acid C18H34O2 282.46 CCCCCCCCC=CCCCCCCCC(=O)O
TCMBANKIN061570 curcumin (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; Curcumin; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; Kacha haldi; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; ZINC00899824; 458-37-7; SDCCGMLS-0066836.P001; SCHEMBL2622435; Spectrum3_001990; DivK1c_006683; KBio1_001627; SpecPlus_000587; SPBio_001728; Spectrum2_001714; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; NSC32982; Turmeric oleoresin (79%-85% curcumin); Yellow Root; Halad; Diferaloylmethane; kachs haldi; safra d'inde; Curcumin, 95% (total curcuminoid content), from Turmeric rhizome; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; GTPL7000; Turmeric, oleoresin; CI 75300; MFCD00008365; curcuma longa l. root oil hydrodistilled; DSSTox_CID_1421; NSC-687842; C21H20O6; Merita earth; NCGC00017159-11; 1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; NCGC00017159-06; I06-2497; BDBM50140172; I14-19358; MLS001148449; LS-125; NCGC00023332-04; SCHEMBL8441; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one; BIDD:ER0479; 458-37-7; Turmeric root oil; Tox21_111505; BDBM50067040; 1790-EP2308861A1; Safran d'Inde; Turmeric oil (Curcuma longa L.); NSC 687842; Tumeric yellow; NCGC00017159-05; Curcuma oil; (1E,6E)-1,7-bis[4-hydroxy-3-(methyloxy)phenyl]hepta-1,6-diene-3,5-dione; 2,7-Nonadiene-4,6-dione, 1,9-bis(4-hydroxy-3-methoxyphenyl)-; EINECS 207-280-5; 15845-47-3; E 100; Curcuma longa l. oleoresin; Curcuma longa l. root oleoresin; SR-01000000149-2; NCGC00017159-10; D0H8LC; HMS3649K06; Turmeric oleoresin; Orange Root; Curcumin (Natural); Indian saffron; Curcumin, United States Pharmacopeia (USP) Reference Standard; NCGC00017159-07; CCG-36107; Curcumin solution, ~0.1 % (w/v) (in ethanol with 2M HCl (99:1 v/v)), for TLC derivatization; 5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcurmin; 1,5-Di(vanillyliden)acetylaceton; I06-0010; Natural yellow 3; SMR000058237; cid_969516; Zlut prirodni 3; CHEMBL140; CAS-458-37-7; Curcumin, analytical standard; BG0601; ZX-AT003872; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione #; BCP9000557; Yellow puccoon; Tumeric oleoresin; DB11672; 1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione; BG00706978; NSC687842; AC1LJ6T6; SCHEMBL8440; SR-01000000149; Tox21_201116; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; J10108; C.I. Natural Yellow 3; (1E,4Z,6E)-5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcumin (synthetic); BIC8500; NCGC00017159-09; CCRIS 5804; NCGC00023332-05; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; W-5038; 1,7-DI(4-HYDROXY-3-METHOXYPHENYL)HEPTA-1,6-DIENE-3; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, (E,E)-; FEMA No. 3086; 1790-EP2305629A1; BB_NC-01422; BC678109; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-; WLN: 1OR BQ E1U1V1V1U1R DQ CO1; Yellow Ginger; Diferuloylmethane; BRN 2306965; Bio-0677; AC1Q46A0; 98% curcurmin); cid_5281767; ZINC899824; Oils, galangal; 33171-04-9; (1E,6E)-1,7-bis(3-methoxy-4-oxidanyl-phenyl)hepta-1,6-diene-3,5-dione; curcuma longa l. root oil CO2 extract; Gelbwurz; OR24598; Oil of turmeric; Curcuma oil (Curcuma longa); MLS000069631; 1,5-Divanillyliden-2,4-pentandion; BDBM29532; 1,7-bis(4-hydroxy-3-methoxyphenyl)1,6-heptadiene-3,5-dione; UNII-IT942ZTH98; Yellow, Turmeric; BCP0726000035; Tox21_110803; KB-251224; CU-01000001305-2; Turmeric oil; HMS2233K04; D07SDQ; ST055629; Curcumin, primary pharmaceutical reference standard; CCG-36020; BRD-K07572174-001-19-6; MolPort-001-763-682; DSSTox_GSID_31077; DSSTox_RID_78861; Turmeric; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; NSC-32982; Kacha haldi; HY-N0005; Kurkumin [Czech]; Haldar; PREVENTION 4 (CURCUMIN) (SEE ALSO TUMERIC, OLEORESIN (10105-J)); (1Z,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; Turmeric (>98% curcurmin); GP8291; M212; Zlut prirodni 3 [Czech]; VFLDPWHFBUODDF-FCXRPNKRSA-N; LS-2189; Turmeric yellow; Turmeric extract (Curcuma longa L.); Curcumin; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; TR-032605; Curcuma longa l. root oil; FEMA No. 3085; curouma; Tu rmeric root oil; Opera_ID_1627; AC-24238; 73729-23-4; Halud; 1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; RTR-032605; Yo-Kin; NCGC00023332-03; trans,trans-Curcumin; Curcuma longa l. oil; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)-; IT942ZTH98; (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; diferuloylmethan; cMAP_000052; N1839; 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; BG01656528; Curcuma; CCRIS 3257; Diferulylmethane; Curcumin, >=94% (curcuminoid content), >=80% (Curcumin); NCGC00017159-04; SC-17381; BRD-K07572174-001-22-0; turmeric root oil hydrodistilled; Oils, curcuma; 458C377; Hydrastis; AK316302; Haldar, Souchet; Natural Yellow3; 4-08-00-03697 (Beilstein Handbook Reference); E 100 (Dye); 1,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; CS-1490; Indian turmeric; (1E,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; ((E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione); Kurkumin; Curcumin I; Souchet; (1E,6E)-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,6-diene-3,5-dione; HSDB 4334; Haidr; NCI-C61325; BBL027711; Golden seal; SCHEMBL13521974; CC0179; 1,3-Di(3-methoxy-4-hydroxystyryl)propanedial; Terra Merita; NCGC00258668-01; SBB006495; Curcumin, matrix substance for MALDI-MS, >=99.5% (HPLC); STL371943; AN-23454; CURCUMIN (SEE ALSO TUMERIC, OLEORESIN (10105-J)); 8024-37-1; Curcuma longa oils; 91884-86-5; AKOS001305497; BRD-K07572174-001-02-2; Turmeric extract; TURMERIC, OLEORESIN (CURCUMIN) (SEE ALSO CURCURMIN (458-37-7)); CI Natural Yellow 3; Cucurmin; CHEBI:3962; DTXSID8031077; DB-002681; Curcumine; Turmeric root oleoresin; curcumin; turmeric root oil CO2 extract; Curcumin, from Curcuma longa (Turmeric), powder; NCGC00017159-12; 79257-48-0; C.I. 75300; 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadien-3,5-dione; NSC 32982; SR-01000000149-5, curcumine;curcumin IC21H20O6 368.4 g/mol COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O

   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000009 Neoplasms Abnormality of the nervous system; Neoplasm Neoplastic Process disease
TCMBANKDI000011 Pathological Conditions, Signs and Symptoms Abnormality of the digestive system; Constitutional symptom Sign or Symptom phenotype
TCMBANKDI000018 Digestive System Diseases; Neoplasms; Endocrine System Diseases Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI000054 Nervous System Diseases; Mental Disorders Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI000061 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process group
TCMBANKDI000071 Digestive System Diseases; Chemically-Induced Disorders - Disease or Syndrome disease
TCMBANKDI000092 Respiratory Tract Diseases Abnormality of the respiratory system Disease or Syndrome disease
TCMBANKDI001110 Neoplasms Neoplasm Neoplastic Process disease
TCMBANKDI001279 Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Cardiovascular Diseases Abnormality of the nervous system; Abnormality of blood and blood-forming tissues; Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI001299 Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Cardiovascular Diseases Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI002974 Neoplasms - Neoplastic Process disease
TCMBANKDI003248 Nutritional and Metabolic Diseases; Endocrine System Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease
TCMBANKDI003353 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process phenotype
TCMBANKDI005370 Pathological Conditions, Signs and Symptoms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases Constitutional symptom; Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI006819 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Eye Diseases - Disease or Syndrome disease
TCMBANKDI007091 Neoplasms - Neoplastic Process phenotype
TCMBANKDI007618 Hemic and Lymphatic Diseases Abnormality of blood and blood-forming tissues Disease or Syndrome phenotype
TCMBANKDI008017 Neoplasms - Neoplastic Process disease
TCMBANKDI009152 - - Congenital Abnormality disease
TCMBANKDI009951 Nutritional and Metabolic Diseases; Musculoskeletal Diseases Abnormality of the skeletal system Disease or Syndrome disease
TCMBANKDI011071 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Eye Diseases; Skin and Connective Tissue Diseases - Disease or Syndrome; Congenital Abnormality disease
TCMBANKDI011458 Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI011743 Neoplasms; Skin and Connective Tissue Diseases Neoplasm; Abnormality of the breast Neoplastic Process group
TCMBANKDI012157 Nervous System Diseases Abnormality of the nervous system Disease or Syndrome group
TCMBANKDI012976 Neoplasms; Stomatognathic Diseases - Neoplastic Process disease
TCMBANKDI013007 Pathological Conditions, Signs and Symptoms - Pathologic Function phenotype
TCMBANKDI013495 Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process group
TCMBANKDI014839 Nutritional and Metabolic Diseases; Immune System Diseases; Endocrine System Diseases - Disease or Syndrome disease
TCMBANKDI015452 Neoplasms; Endocrine System Diseases Abnormality of the endocrine system; Neoplasm Neoplastic Process disease
TCMBANKDI015491 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Musculoskeletal Diseases; Nervous System Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI016026 Neoplasms; Eye Diseases Neoplasm; Abnormality of the eye Neoplastic Process disease
TCMBANKDI016890 Digestive System Diseases; Neoplasms - Neoplastic Process disease
TCMBANKDI016946 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases; Respiratory Tract Diseases - Disease or Syndrome disease
TCMBANKDI017024 Neoplasms; Respiratory Tract Diseases - Neoplastic Process disease
TCMBANKDI018635 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI018731 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI020559 Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases - Disease or Syndrome disease
TCMBANKDI020911 Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases - Disease or Syndrome disease
TCMBANKDI020912 Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases - Disease or Syndrome disease
TCMBANKDI021600 Neoplasms - Neoplastic Process disease
TCMBANKDI023140 Neoplasms; Endocrine System Diseases Abnormality of the endocrine system; Neoplasm Neoplastic Process disease
TCMBANKDI023464 Nervous System Diseases Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI024035 Neoplasms Neoplasm Neoplastic Process disease
TCMBANKDI024262 - - Neoplastic Process phenotype
TCMBANKDI024293 Neoplasms Neoplasm Neoplastic Process disease
TCMBANKDI024535 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI025420 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI025428 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Stomatognathic Diseases - Disease or Syndrome disease
TCMBANKDI026158 Musculoskeletal Diseases; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI027339 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process disease
TCMBANKDI028504 - - Neoplastic Process disease
TCMBANKDI028561 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases - Neoplastic Process disease
TCMBANKDI029899 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process group
TCMBANKDI030540 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI032357 - Abnormality of the digestive system Finding phenotype
TCMBANKDI032496 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis Disease or Syndrome disease
TCMBANKDI032498 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease